The effect of capsular extract of Morus Alba leaves on nephropathic complications of diabetes mellitus type 2

A clinical trial the effect of hydroalcoholicl extracts of Morus Alba leaves capsules on nephropathic complications of diabetic patients type 2

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016021512438N18

Enrollment

Registered

2016-06-08

Start date

2016-04-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy. Non-insulin-dependent diabetes mellitus with renal complications

Interventions

Intervention 1: control group: routine treatment+ placebo cap BID, 2 months. Intervention 2: intervention group: routine treatment+ extract of Morus Alba leaves cap BID,2 months.

Placebo

Treatment - Drugs

control group: routine treatment+ placebo cap BID, 2 months

intervention group: routine treatment+ extract of Morus Alba leaves cap BID,2 months

Eligibility

Sex/Gender

All

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: patients 35 to 70 years old receiving reducer blood glucose drug and dietary recommendations for 3 to 5 years with type II diabetes. That LDL-cholesterol less than 130 and triglycerides less than 300. Exclusion criteria: liver disease, allergies to plants used in the clinical trial, changing the dose of drug during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting plasma glucose. Timepoint: Baseline and End-of-tria. Method of measurement: blood sample.;Lipid profile. Timepoint: Baseline and End-of-tria. Method of measurement: blood sample.;Insulin. Timepoint: Baseline and End-of-tria. Method of measurement: blood sample.;Total anti oxidant capacity(TAC). Timepoint: Baseline and End-of-tria. Method of measurement: blood sample.;Alanine aminotransferase(ALT), Aspartate aminotransferase(AST). Timepoint: Baseline and End-of-tria. Method of measurement: blood sample.;Hs-CRP. Timepoint: Baseline and End-of-tria. Method of measurement: blood sample.;Blood urea nitrogen. Timepoint: Baseline and End-of-tria. Method of measurement: urine sample.;CREATININ. Timepoint: Baseline and End-of-tria. Method of measurement: urine sample.;PRO. Timepoint: Baseline and End-of-tria. Method of measurement: urine sample.;HbA1C. Timepoint: Baseline and End-of-tria. Method of measurement: percent of glycosylated hemoglobin.	—

Measure

Time frame

Fasting plasma glucose. Timepoint: Baseline and End-of-tria. Method of measurement: blood sample.;Lipid profile. Timepoint: Baseline and End-of-tria. Method of measurement: blood sample.;Insulin. Timepoint: Baseline and End-of-tria. Method of measurement: blood sample.;Total anti oxidant capacity(TAC). Timepoint: Baseline and End-of-tria. Method of measurement: blood sample.;Alanine aminotransferase(ALT), Aspartate aminotransferase(AST). Timepoint: Baseline and End-of-tria. Method of measurement: blood sample.;Hs-CRP. Timepoint: Baseline and End-of-tria. Method of measurement: blood sample.;Blood urea nitrogen. Timepoint: Baseline and End-of-tria. Method of measurement: urine sample.;CREATININ. Timepoint: Baseline and End-of-tria. Method of measurement: urine sample.;PRO. Timepoint: Baseline and End-of-tria. Method of measurement: urine sample.;HbA1C. Timepoint: Baseline and End-of-tria. Method of measurement: percent of glycosylated hemoglobin.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mohsen Taghizadeh

Kashan University of Medical Sciences

mohsenta44@yahoo.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026